Keynote presentation by Romanas Ramanauskas at Swedish&Danish Life Science conference, 8 April 2015 Medicon Village, Lund, Sweden

1. Success factors of life sciences
sector in Lithuania: from academic
research to industrial leadership
Romanas Ramanauskas, MSc, EMBA
Expert @ Open R&D Lithuania
Founder @ Vilnius Biotech
The Future of Swedish & Danish Life Science, April 8, 2015
Medicon Village, Lund, Sweden

2. 2
Agenda
⇁ Why Lithuania?
⇁ Success factors
⇁ “Open R&D Lithuania” network
⇁ A case for Lithuanian biotech industry

3. 3
Why Lithuania?
⇁ Lithuania’s life sciences industry grow
more than 20% annually and export to
over 70 countries
⇁ Our true champions are biotechnology,
pharma and medical devices
contributing exceptionally large part of
GDP
⇁ Biopharmaceutical and MedTech
products from Vilnius made their way to
the most regulated markets, including
US

4. 4
Success factors for Lithuanian
life sciences
⇁ Focus on product-to-market and
bioprocess innovations
⇁ Two decades of industrial leadership
and successful integration with global
value chains
⇁ Ready available 3000 researchers’ pool
in life sciences and attractive investment
climate
⇁ Strict compliance to EU and US
regulatory standards both in R&D and
manufacturing

5. 5
Success factors for Lithuanian
life sciences
⇁ Lithuania become attractive location for
global R&D-intensive business enjoying
No. 1 rank on FDI projects per capita in EU
⇁ With recent 200+ MEUR public investment
into research infrastructure, Lithuania will
house the largest collaborative R&D platform
in CEE region
⇁ Global life sciences corporations
choose Lithuania for their R&D and
Manufacturing operations – growing trend
for the recent decade

6. 6
Globalization of Lithuanian
life sciences industry
⇁ First Lithuanian life sciences companies were founded in 90s
⇁ During last 10 years they joined global multinational corporations:
• BIOTECHNA: 150 employees biopharmaceutical company developing and
producing two biosimilar drugs  became a part of TEVA (Israel)
• VILTECHMEDA: 70 employees MedTech company developing and
manufacturing syringe pumps  was sold to MOOG Medical Devices (US)
• FERMENTAS: 350 employees biotech restriction enzymes developer &
producer operating worldwide  merged with Thermo Fisher Scientific (US)
• SANITAS: 130 employees Stock Exchange listed generic drugs manufacturer
operating in CEE  has been acquired by Valeant Pharma (Canada)

7. 7
Open R&D Lithuania - research
and collaboration network
⇁ Open R&D Lithuania is academic driven
research network, aimed to provide attractive
R&D platform for international partners
⇁ Over 80 MEUR invested in 2010-2015 by
Lithuania State in biotechnology and
biomedical R&D infrastructure to fuel
collaborative and sponsored research
⇁ Vilnius biotech R&D platform include 2
leading universities, 4 research institutes, 3
science and technology parks, State Agency for
science and innovation, as well as Lithuanian
Biotechnology association

8. 8
Vilnius biotechnology cluster
– new developments in 2015
Vilnius now has strongest biomedical research
network in Baltics, powered by leading state owned
research institutions, recently undergone major
facilities upgrade:
⇁ Innovative medicine centre
• 8,500 sqm of lab facilities, 100+ employees
• R&D focus: regenerative medicine, stem cells and
pre-clinical research
⇁ Vilnius life sciences centre
• 24,000 sqm of lab facilities, 400+ employees
• R&D focus: biochemistry, biotechnology and
structural biology research
⇁ Vilnius University hospital campus
• 27 research units and labs, 5000 employees (375
researchers), ~900,000 patients annually
• R&D focus: molecular and digital pathology,
cardiology, hybrid medical imaging, biobanking

9. 9
Lithuanian life sciences
collaboration potential
⇁ Accelerate and scale-up your drug discovery and
drug / process development programs
⇁ Access experienced R&D teams
“on demand” at a fraction of typical outsourcing
costs
⇁ Achieve higher return on investment in your early
stage projects with the same R&D budget
⇁ Avoid transparency issues of classic CRO model
through FTE-based contracts
⇁ Amortize potential R&D failures by increasing
number of candidates in the pipeline
Contact Vilnius Biotech now: BD@vilniusBIO.com

10. Contact Vilnius Biotech now:
BD@vilniusBIO.com
or directly:
Romanas Ramanauskas
phone +370 620 88621
skype romanas.lt
romanas.ramanauskas@btparkas.lt
Let’s stay in touch @LinkedIn

11. 11
A case study:
Lithuanian bio-industry benchmark

12. 12
Lithuania biotechnology
industry benchmarks
⇁ Biotechnology industry sales reached 480 MEUR in 2013
⇁ 10 revenue generating companies and 12 in development
⇁ Industry employs ~1600 people in production, R&D and quality
2012 2013 2012 2013
3 65.3 106.4 306 345
5 177.6 186.1 350 398
2 151.7 186.5 770 830
12 19 21
22 394.5 479.1 1445 1594
Biofuel and green biotech
No of
com-
panies
Other small biotech
Total
Industrial biotechnology
Company type
Sales, MEUR Employee headcount
Healthcare biotechnology

13. 13
Lithuania biotechnology
industry benchmarks
⇁ Biotechnology industry sales reached 480 MEUR in 2013
⇁ 10 revenue generating companies and 12 in development
⇁ Industry employs ~1600 people in production, R&D and quality
Is it big or not?

14. 14
Lithuania is among global
leaders in biotechnology
⇁ Lithuania generate over 1% of GDP from biotech industry
• comparable to Swiss, Israeli or Danish figures
• 10 times more than EU average
⇁ Sales grow 20% annually (30% CAGR over decade)
GDP,
billions EUR
Biotech
ratio
Lithuania 479 34,631 1.38%
Israel (approx.) 2,256 219,173 1.03%
Switzerland 4,473 489,334 0.91%
United States 54,060 12,631,353 0.43%
UK 4,152 1,906,587 0.22%
Germany 3,161 2,733,804 0.12%
EU average 15,759 13,061,367 0.12%
2013
Biotech industry
turnover, MEUR
Lithuania 21.4%
United States 12.9%
Switzerland 9.0%
UK 8.7%
EU average 2.8%
2012-2013 YY growth

15. Thank you!
…and let’s stay in touch @LinkedIn
Romanas Ramanauskas
Biotechnologiju parkas
2A Mokslininku, Vilnius, Lithuania
phone +370 620 88621
fax +370 521 96679
skype romanas.lt
romanas.ramanauskas@vilniusbio.com